SCHEMBL6583019

SCHEMBL6583019

c1ccc(COc2cccc(C3CC3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.56
KCNH2 Q12809 1/20 0.55
KDM1A O60341 1/20 0.55
CYP4F2 P78329 1/20 0.53
CYP4A11 Q02928 1/20 0.53
BCHE P06276 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
GRIN1 Q05586 4/20 0.52
GRIN2B Q13224 1/20 0.52
MAOA P21397 1/20 0.51
NR4A2 P43354 1/20 0.51
SPHK1 Q9NYA1 1/20 0.51
ALOX5 P09917 1/20 0.50
LCK P06239 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6588487 0.94 SPHK1 (0.55) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL6583023 0.94 SPHK1 (0.58) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL29666652 0.93 KCNH2 (0.53) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL12354455 0.92 SPHK1 (0.60) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL12735838 0.90 HTR2C (0.60) MAOBKCNH2KDM1ATNKS2MAOA
SCHEMBL31266264 0.88 KDM1A (0.48) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL27669778 0.87 KDM1A (0.50) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL28190298 0.86 TNKS2 (0.52) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL23380025 0.85 KDM1A (0.48) MAOBKCNH2KDM1ACYP4F2CYP4A11
SCHEMBL23364801 0.85 KCNH2 (0.49) MAOBKCNH2KDM1ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1523015-A 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines �Ʒ� 2004-08-25 CN disclosed
CN-1515554-A Intermediate compound for producing 2-amino-6-(2-substituted-4-phenoxy) substituted pyridine compound �Ʒ� 2004-07-28 CN disclosed
EP-0958282-B1 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES PFIZER PROD INC (US) 2004-07-21 EP disclosed
US-20030162765-A1 Use in treatment and prevention of central nervous system and other disorders PFIZER INC. 2003-08-28 US disclosed
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... PFIZER INC. 2001-07-12 US disclosed
CN-1246848-A 2-amino-6- (2-substituted-4-phenoxy) -substituted pyridines PFIZER PROD INC (US) 2000-03-08 CN disclosed
EP-0958282-A1 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES Pfizer Products Inc. (US) 1999-11-24 EP disclosed
WO-1998034919-A1 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES PFIZER PRODUCTS INC. (US) 1998-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... NOS1, PTGS1, NOS2 MAOB 255/4885KCNH2 2408/4885KDM1A 1259/4885
US-20030162765-A1 Use in treatment and prevention of central nervous system and other disorders GRIN2C, GRIN2A, CNR2 MAOB 96/4885KCNH2 1308/4885KDM1A 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.